Biomarin Pharmaceutical Stock Analysis

Biomarin Stock Analysis Notes

About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Biomarin Pharmaceutical was currently reported as 26.25. The company has Price/Earnings To Growth (PEG) ratio of 0.76. Biomarin Pharmaceutical had not issued any dividends in recent years. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was incorporated in 1996 and is headquartered in San Rafael, California. Biomarin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3045 people. For more info on Biomarin Pharmaceutical please contact JeanJacques Bienaime at 415 506 6700 or go to https://www.biomarin.com.

Biomarin Pharmaceutical Investment Alerts

Biomarin Pharmaceutical Upcoming and Recent Events

Biomarin Largest EPS Surprises

View All Earnings Estimates

Biomarin Stock Institutional Investors

Note, although Biomarin Pharmaceutical's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biomarin Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 17.37 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biomarin Pharmaceutical's market, we take the total number of its shares issued and multiply it by Biomarin Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Biomarin Profitablity

The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.04 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.04.

Management Efficiency

Biomarin Pharmaceutical has return on total asset (ROA) of 0.0163 % which means that it generated a profit of $0.0163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0351 %, meaning that it created $0.0351 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Biomarin Pharmaceutical's Return On Tangible Assets are very stable compared to the past year. As of the 16th of April 2024, Fixed Asset Turnover is likely to grow to 2.28, while Non Currrent Assets Other are likely to drop about 72.7 M.

Technical Drivers

As of the 16th of April 2024, Biomarin Pharmaceutical shows the Risk Adjusted Performance of (0.03), mean deviation of 0.9479, and Standard Deviation of 1.23. Biomarin Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Biomarin Pharmaceutical, which can be compared to its peers. Please confirm Biomarin Pharmaceutical variance and potential upside to decide if Biomarin Pharmaceutical is priced correctly, providing market reflects its regular price of 91.51 per share. Given that Biomarin Pharmaceutical has information ratio of (0.10), we suggest you to validate Biomarin Pharmaceutical's prevailing market performance to make sure the company can sustain itself at a future point.

Biomarin Pharmaceutical Price Movement Analysis

Biomarin Pharmaceutical Insider Trading Activities

Biomarin Pharmaceutical Outstanding Bonds

Biomarin Pharmaceutical Predictive Daily Indicators

Biomarin Pharmaceutical Corporate Filings

Biomarin Pharmaceutical Forecast Models

Biomarin Pharmaceutical's time-series forecasting models are one of many Biomarin Pharmaceutical's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biomarin Pharmaceutical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biomarin Pharmaceutical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biomarin shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Biomarin Pharmaceutical. By using and applying Biomarin Stock analysis, traders can create a robust methodology for identifying Biomarin entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biomarin analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biomarin analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Biomarin Pharmaceutical stock analysis indicators help investors evaluate how Biomarin Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biomarin Pharmaceutical shares will generate the highest return on investment. By understating and applying Biomarin Pharmaceutical stock analysis, traders can identify Biomarin Pharmaceutical position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.